Glycan characterisation

Waters has released the UltraPerformance LC (UPLCÂ) analytical solution for the characterisation of 2-AB labelled glycans from glycoproteins. The UPLC solution combines the Acquity UPLC BEH Glycan Columns with the Acquity UPLC System equipped with fluorescence detection. Current FDA regulations require that firms developing and manufacturing therapeutic proteins are able to accurately characterise the glycans attached to those proteins to ensure the efficacy and safety of a biopharmaceutical product.

Waters is introducing this solution at the request of scientists seeking to apply the power of UPLC technology to the development and analysis of glycans derived from therapeutic proteins.

Initial user feedback has shown the UPLC solution to be up to three times faster than traditional HPLC for the analysis of 2-aminobenzamide (2AB)-labelled glycans from human IgG. In addition, to ensure confidence in long-term use in customer validated methods, all Acquity UPLC BEH Glycan columns are quality control tested with relevant labelled glycan standards for consistent batch-to-batch column performance.

The UPLC BEH Glycan columns provide good resolution for a wide range of glycans and represent the fifth application-tested UPLC column and eleventh UPLC chemistry added to the Acquity UPLC column family.